Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 543Neoplasms 449Carcinoma, Non-Small-Cell Lung 410Prostatic Neoplasms 334Colorectal Neoplasms 315Lung Neoplasms 261Multiple Myeloma 229Neoplasm Metastasis 190Pancreatic Neoplasms 186Leukemia, Myeloid, Acute 183Ovarian Neoplasms 178Melanoma 147Squamous Cell Carcinoma of Head and Neck 140Carcinoma, Hepatocellular 116Recurrence 115Head and Neck Neoplasms 114Carcinoma, Renal Cell 112Lymphoma 111Stomach Neoplasms 110Endometrial Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Glioblastoma 108Brain Neoplasms 106Lymphoma, Non-Hodgkin 105Uterine Cervical Neoplasms 100Triple Negative Breast Neoplasms 97Urinary Bladder Neoplasms 95Hematologic Neoplasms 91Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84

Interventions

tovorafenib 1Carboplatin 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Noonan Syndrome 5 × 30 days × Clear all
NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡